• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
  • Contact

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Psoriasis Market Global Analysis and Pipeline Landscape Assessment for H2 2016
  • USA - English


News provided by

ReportsnReports

Oct 28, 2016, 02:00 ET

Share this article

Share this article


PUNE, India, October 28, 2016 /PRNewswire/ --

ReportsnReports.com adds "Psoriasis - Pipeline Review, H2 2016" market research report to its store, providing comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects.

Complete report on Global Psoriasis Market Research with 222 market data tables and 17 figures, spread across 699 pages is available at http://www.reportsnreports.com/reports/729123-psoriasis-pipeline-review-h2-2016.html.

Company Analysis and Positioning discussed in this research are AbbVie Inc, Abeome Corporation, AbGenomics International, Inc., Addex Therapeutics Ltd, Advinus Therapeutics Ltd, Affibody AB, Albireo AB, Almirall, S.A., Alteogen Inc., Amgen Inc., Anacor Pharmaceuticals, Inc., AnaptysBio, Inc., ApoPharma Inc., Arena Pharmaceuticals, Inc., Argos Therapeutics, Inc., Arrien Pharmaceuticals, LLC, AstraZeneca Plc, Athenex, Inc., Aurigene Discovery Technologies Limited, Aurinia Pharmaceuticals Inc, Avexxin AS, Betta Pharmaceuticals Co. Ltd., BioApex, s.r.o., BIOCAD, Biocon Limited, BioLingus AG, BioMAS Ltd., Biomics Biotechnologies Co., Ltd., Bionomics Limited, Bionovis SA, Boehringer Ingelheim GmbH, Brickell Biotech, Inc., Bristol-Myers Squibb Company, C4X Discovery Holdings PLC, CalciMedica, Inc., Can-Fite BioPharma Ltd., Celgene Corporation, Cell Medica Limited, Cellceutix Corporation, ChemoCentryx, Inc., Chipscreen Biosciences Ltd, ChironWells GmbH, Clonz Biotech Private Limited, Coherus BioSciences, Inc., Compugen Ltd., Convoy Therapeutics, Inc., Creabilis SA, Crescendo Biologics Limited, Curapel Limited, Cutanea Life Sciences, Inc., Dermala Inc, Domainex Limited, Dr. August Wolff GmbH & Co. , KG Arzneimittle, EA Pharma Co Ltd, Eli Lilly and Company, Epirus Biopharmaceuticals, Inc., Exicure, Inc., Foamix Pharmaceuticals Ltd., Forward Pharma A/S, Gem Pharmaceuticals, LLC, Genentech, Inc., Genor BioPharma Co., Ltd., GlaxoSmithKline Plc, GlycoMar Limited, Grupo Ferrer Internacional, S.A., HitGen LTD, Huabo Biopharm Co., Ltd., Hydra Biosciences, Inc., iCo Therapeutics Inc., Idera Pharmaceuticals, Inc., Immune Pharmaceuticals Inc., Immune Response BioPharma, Inc., Immungenetics AG, Innovent Biologics, Inc., Jenrin Discovery, Inc., Johnson & Johnson, Kadmon Corporation, LLC, KaloBios Pharmaceuticals, Inc., KPI Therapeutics, Inc., Lead Pharma Holding B.V., Lee's Pharmaceutical Holdings Limited, LEO Pharma A/S, Lipidor AB, Lupin Limited, Lycera Corp., mAbxience S.A., Maruho Co., Ltd., Medestea Research & Production S.p.A., MediGene AG, Merck KGaA, MetrioPharm AG, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Inc., Mycenax Biotech Inc., NeuClone Pty Ltd, Nimbus Therapeutics, LLC, NovaLead Pharma Pvt. Ltd., Novan, Inc., Novartis AG, Nuevolution AB, Numedii, Inc., Oncobiologics, Inc., OSE Immunotherapeutics, Panacea Biotec Limited, Pfizer Inc., Pharis Biotec GmbH, Pharmedartis GmbH, Phenex Pharmaceuticals AG, Pieris Pharmaceuticals Inc, PinCell srl, Promius Pharma, LLC, Protalix BioTherapeutics, Inc., Prothena Corporation Plc, Provectus Biopharmaceuticals, Inc., RedHill Biopharma Ltd., Rigel Pharmaceuticals, Inc., Sandoz International GmbH, Sareum Holdings Plc, Selvita S.A., Shanghai Celgen Bio-Pharmaceutical Co., Ltd., Shulov Innovative Science Ltd., Sigmoid Pharma Limited, Soligenix, Inc., Spherium Biomed S.L., Stemline Therapeutics, Inc., sterna biologicals Gmbh & Co KG, Sucampo Pharmaceuticals, Inc., Sun Pharma Advanced Research Company Ltd., SWITCH Biotech LLC, Syntrix Biosystems, Inc., Takeda Pharmaceutical Company Limited, Tasly Pharmaceutical Group Co., Ltd., Telormedix SA, Teva Pharmaceutical Industries Ltd., TheraMAB LLC, Therapeutic Proteins International, LLC, Therapix Biosciences Ltd., UCB S.A., Valeant Pharmaceuticals International, Inc., Vitae Pharmaceuticals, Inc., Wellstat Therapeutics Corporation, XBiotech Inc, XenoPort, Inc., Yuhan Corporation and Ziarco Pharma Ltd.

Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=729123.

Psoriasis pipeline therapeutics constitutes close to 264 molecules. Out of which approximately 247 molecules are developed by Companies and remaining by the Universities/Institutes. Currently, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 25, 39, 29, 2, 96, 37 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 10 and 7 molecules, respectively.

Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful Psoriasis drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies - such as Opdivo, which was recently approved for renal cell carcinoma. The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Explore more reports on Pharmaceuticals.

About Us:   

ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.


Contact:
Ritesh Tiwari
2nd floor, metropole, Next to Inox theatre, Bund garden road
Pune-411001
Maharashtra, India
Tel:  +1-888-391-5441
[email protected]

Connect With Us on:

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds: http: //http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports

Modal title

Also from this source

1,4-Butanediol Market Global Key Players, Demands, Sales, Growth rate, Size, Share and Forecast to 2027 - ReportsnReports


Activated Carbon Fiber Market Global Key Players, Demands, Size, Share, Growth Rate, Cost, Production, Application and Forecasts to 2027 - ReportsnReports

Explore

More news releases in similar topics

  • Health Care & Hospitals
  • Medical Pharmaceuticals
  • Surveys, Polls and Research

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2023 Cision US Inc.